Market Overview

LaVoieHealthScience Adds XenoTherapeutics to Client Roster

Share:

Boston-based XenoTherapeutics Aims to Bring Life-Saving Innovation
from The Lab to Address the Global Shortage of Transplantable Organs and
Tissues

LaVoieHealthScience
(LHS), an integrated investor and public relations agency focused on
advancing health and science innovations, today announced the addition
of XenoTherapeutics to its client roster as its agency of record for
strategic communications. XenoTherapeutics is partnering with LHS to
build a messaging framework to educate stakeholders on the company's
proprietary platform technology to advance xenotransplantation, the
science of transplanting organs and tissues of different species.

XenoTherapeutics' mission is to provide innovative, affordable, and safe
medical solutions to patients in critical need in both the U.S. and
around the globe. Its initial product candidate, Xeno-Skin, is
intended to serve as a replacement or a complement to the current "gold
standard" of burn treatment: human cadaver allograft. However, unlike
the limited quantity of lifesaving human graft material available, Xeno-Skin
is intended to be mass-produced, stored, and rapidly shipped when
needed. Ultimately, the goal is to increase emergency preparedness for
unexpected catastrophic events at home and fill current shortages
experienced far too frequently around the world today. The
XenoTherapeutics pipeline starts with skin, but envisions myriad
applications of the technology, including nerves and solid organs.

"In selecting a communications partner, we did our due diligence," said
Paul Holzer, Co-founder and Chief Executive Officer of XenoTherapeutics.
"LHS stood out with its deep understanding of the business and
regulatory aspects of science and medicine, its team of high-touch
senior leaders, and proprietary approach to creating targeted messaging
mapped to stakeholders as the underpinning of a strategic communications
program. We are looking forward to a long and fruitful relationship."

Donna L. LaVoie, President & CEO of LaVoieHealthScience commented, "We
are delighted to be working with the XenoTherapeutics team to bring
attention to their pioneering work in seeking to address the worldwide
shortage of organs for transplantation. Headed by a former U.S. Navy
SEAL, XenoTherapeutics' entrepreneurial culture, sense of purpose, and
innovative technology based on rigorous scientific research has the
potential to be an industry game-changer."

About XenoTherapeutics

XenoTherapeutics' goal is to provide safe, scalable transplantation
solutions based on three decades of research by some of the world's top
leaders in xenotransplantation, surgery and infectious disease. The
company's proprietary platform leverages genetically-engineered pigs to
provide a supply of temporary tissues and organs that are less
susceptible to human rejection.

The company has developed a non-human organ transplant solution
currently under investigational review by the FDA, which has the
potential to catalyze the science of xenotransplantation and address a
critically unmet need for organs and tissues across the globe. For more
information, please visit: https://www.xenotherapeutics.org/

About LaVoieHealthScience

LaVoieHealthScience provides integrated strategic communications and
investor relations services to build recognition and increase sales and
value for health science innovations. For more information, please
visit: https://lavoiehealthscience.com/

View Comments and Join the Discussion!